Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Change in Account Payables (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Change in Account Payables data on record, last reported at -$1.5 million in Q3 2025.

  • For Q3 2025, Change in Account Payables fell 424.03% year-over-year to -$1.5 million; the TTM value through Sep 2025 reached -$477000.0, down 188.01%, while the annual FY2024 figure was -$468000.0, 216.13% down from the prior year.
  • Change in Account Payables reached -$1.5 million in Q3 2025 per MBRX's latest filing, down from $850000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $2.2 million in Q2 2023 and bottomed at -$2.1 million in Q3 2023.
  • Average Change in Account Payables over 5 years is $49684.2, with a median of -$26000.0 recorded in 2021.
  • The widest YoY moves for Change in Account Payables: up 433.91% in 2022, down 5565.38% in 2022.
  • A 5-year view of Change in Account Payables shows it stood at -$26000.0 in 2021, then plummeted by 5565.38% to -$1.5 million in 2022, then soared by 133.27% to $490000.0 in 2023, then tumbled by 206.12% to -$520000.0 in 2024, then tumbled by 185.19% to -$1.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were -$1.5 million in Q3 2025, $850000.0 in Q2 2025, and $676000.0 in Q1 2025.